Esophageal Adenocarcinoma
121
42
53
30
Key Insights
Highlights
Success Rate
68% trial completion
Published Results
20 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.6%
14 terminated out of 121 trials
68.2%
-18.3% vs benchmark
5%
6 trials in Phase 3/4
67%
20 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (121)
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
Obeticholic Acid for Prevention in Barrett's Esophagus
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma